Disciplined Investments’s 10x Genomics TXG Stock Holding History

Disciplined Investments’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	–	–	1632
2022 Q1	$0	Buy	+2	New	+$175	﹤0.01%	1625

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Disciplined Investments's TXG Position: Q2 2022 in Review

Disciplined Investments sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 2 shares.

Disciplined Investments first reported a position in TXG in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

Disciplined Investments reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
Disciplined Investments sold 2 10x Genomics shares in Q2 2022.
Disciplined Investments first reported a position in 10x Genomics in Q1 2022 and held it in 1 quarter.
Disciplined Investments's 10x Genomics position peaked at $0 in Q1 2022.
254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Disciplined Investments's 13F filing for Q2 2022, filed 9 Aug 2022.